Effects of statins on serum n-3 to n-6 polyunsaturated fatty acid ratios in patients with coronary artery disease

J Cardiovasc Pharmacol Ther. 2013 Jul;18(4):320-6. doi: 10.1177/1074248412473202. Epub 2013 Jan 15.

Abstract

Background: A low n-3 to n-6 polyunsaturated fatty acids (PUFAs) ratio is reported to be associated with cardiovascular events. However, the effects of statins on this ratio have not been fully examined.

Methods: A total of 101 patients with coronary artery disease, who were not receiving lipid-lowering therapy were randomly assigned to receive either 4 mg/day of pitavastatin or 20 mg/day of pravastatin. Serum PUFA levels were measured at baseline and 8 months after treatment with statins.

Results: Pitavastatin was used to treat 51 patients and the remaining 50 patients were treated using pravastatin. A significant positive correlation was observed between the percent change in low-density lipoprotein cholesterol and that in dihomogamma-linolenic acid (r = .376, P = .007), arachidonic acid (AA; r = .316, P = .02), eicosapentaenoic acid (EPA; r = .408, P = .003), or docosahexaenoic acid (DHA; r = .270, P = .056) in the pitavastatin group. However, these correlations were not observed in the pravastatin group. The DHA/AA ratio decreased significantly in the pitavastatin group only (from 0.96 to 0.83, P = .0002) and the DHA/AA ratio was significantly lower in the pitavastatin group at 8 months (0.83 vs 0.96, P = .03). The EPA/AA ratio did not show significant changes in either group.

Conclusions: Pitavastatin decreased the serum DHA/AA ratio, whereas pravastatin had no effect on this ratio. Neither pitavastatin nor pravastatin had an effect on the serum EPA/AA ratio in patients with coronary artery disease.

Keywords: coronary artery disease; polyunsaturated fatty acids; statin.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Arachidonic Acid / blood
  • Cholesterol, LDL / blood
  • Cholesterol, LDL / drug effects*
  • Coronary Artery Disease / blood
  • Coronary Artery Disease / drug therapy*
  • Docosahexaenoic Acids / blood
  • Eicosapentaenoic Acid / blood
  • Fatty Acids, Omega-3 / blood*
  • Fatty Acids, Omega-6 / blood*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Japan
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Pravastatin / therapeutic use
  • Prospective Studies
  • Quinolines / therapeutic use
  • alpha-Linolenic Acid / blood

Substances

  • Cholesterol, LDL
  • Fatty Acids, Omega-3
  • Fatty Acids, Omega-6
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Quinolines
  • alpha-Linolenic Acid
  • Docosahexaenoic Acids
  • Arachidonic Acid
  • Eicosapentaenoic Acid
  • Pravastatin
  • pitavastatin